New Advances in Diabetes Drugs Transforming Treatment of Liver Disease
GLP-1 RAs, particularly semaglutide, are showing robust clinical data for liver disease with significant rates of disease resolution and improvement in liver fibrosis.
#mash
2 stories
FDA Grants Survodutide Breakthrough Therapy Designation for MASH
The FDA granted breakthrough therapy designation to survodutide, a dual glucagon/GLP-1 receptor agonist by Boehringer Ingelheim, for treating adults with MASH.